Product Description
Hugel is developing bmt-101, an Injection Protein Synthesis Inhibitor for Hypertrophic Scar
Mechanisms of Action: Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hugel
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| HG-BMT-PI-01 | P1 |
Completed |
Healthy Volunteers |
2018-02-14 |
2019-03-21 |
Treatments |
|
| HG-BMT-PIIa-01 | P2 |
Terminated |
Unknown |
2023-05-10 |
12% |
2023-05-25 |
Primary Endpoints|Treatments |